E. Ohman J or Asset Management AB Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

E. Ohman J or Asset Management AB increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,970 shares of the biopharmaceutical company’s stock after buying an additional 540 shares during the period. E. Ohman J or Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $3,540,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in REGN. Adirondack Trust Co. grew its stake in Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the period. UMB Bank n.a. boosted its holdings in Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Trust Co. of Vermont grew its position in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 12 shares in the last quarter. Nvwm LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.6% during the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on REGN shares. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of Regeneron Pharmaceuticals stock opened at $666.85 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $663.43 and a 1-year high of $1,211.20. The company has a market capitalization of $73.28 billion, a P/E ratio of 16.50, a PEG ratio of 1.60 and a beta of 0.08. The business’s fifty day moving average price is $720.81 and its two-hundred day moving average price is $921.72. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.53%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.